



Mini Review

Copy Right@ Sabina Pistolesi

# Novel Biomarkers are Emerging in Cervical Adenocarcinoma: A Short Review

Sabina Pistolesi<sup>1\*</sup>, Giuseppe Nicolò Fanelli<sup>1,2</sup>, Antonio Giuseppe Naccarato<sup>1,2</sup> and Angiolo Gadducci<sup>3</sup>

<sup>1</sup>Department of Laboratory Medicine, University Hospital, Italy

<sup>2</sup>Department of Translational Research & New Technologies in Medicine & Surgery, University of Pisa, Italy

<sup>3</sup>Department of Clinical and Experimental Medicine, University of Pisa, Italy

\*Corresponding author: Sabina Pistolesi, First Division of Pathology, Department of Laboratory Medicine, Pisa University Hospital, Italy.

**To Cite This Article:** Sabina Pistolesi, Giuseppe Nicolò Fanelli, Antonio Giuseppe Naccarato and Angiolo Gadducci. Novel Biomarkers are Emerging in Cervical Adenocarcinoma: A Short Review. *Am J Biomed Sci & Res.* 2023 18(1) AJBSR.MS.ID.002423, DOI: [10.34297/AJBSR.2023.18.002423](https://doi.org/10.34297/AJBSR.2023.18.002423)

**Received:** 📅 January 27, 2023; **Published:** 📅 February 09, 2023

## Abstract

In recent years, the search for traditional Chinese medicines (TCM) for treating patients with critical and/or life-threatening diseases has attracted much attention in the pharmaceutical industry. However, the evaluation of safety and efficacy of a TCM under investigation has been criticized due to its subjectivity (i.e., experience based rather than scientific based). Thus, statistical validation of study endpoints (usually based on a quality of-life-like instrument) is essential to have an accurate and reliable clinical assessment of the performance of the TCM under study. Hsiao et al. [1] proposed some statistical methods for calibration/validation of Chinese study endpoints against Western clinical endpoints in terms of the performance characteristics of validity, reliability, and ruggedness under a valid study design. In this article, we proposed some innovative study designs for calibration/validation of Chinese study endpoints against Western clinical endpoints. under certain considerations of study design.

**Keywords:** Validity, Reliability, Calibration, Validation

## Introduction

Cervical adenocarcinoma (ADC) represents a heterogeneous group of tumors, associated with different biological behaviors and variable outcomes [1]. Although their prevalence has increased over the past decades, reaching the 20-25% of all cervical malignancies in developed countries [2-4], there are still less frequent than the squamous cervical carcinoma (SCC). For this reason, there are no large series' studies in literature and consequently the oncogenetic pathways of ADC have not been fully elucidated yet.

### The Question Is: Which Biomarkers Might Have a Predictive Role?

The role of infection with human papillomaviruses (HPV) is well-known, however it is not sufficient to induce carcinogenesis: further genetic and epigenetic alterations, as well as the peculiar interaction between infected cells, host immune response and tumor microenvironment (TME) are necessary to promote malignant transformation and progression. Some examples.

a) Genomic alterations in phosphoinositide 3-kinase (PI3K) are detected also in cervical cancer [5,6], associated to mutations of PTEN, MAPK and AKT1 [7-11].

b) A hypoxic TME and an altered neo-angiogenesis is a common feature in solid tumors. In cervical cancer, a high expression level of hypoxia-inducible factor 1 $\alpha$ (HIF-1 $\alpha$ ) is associated with a worse prognosis [12-14].

c) In general, we could assume that immunosuppressive and immunogenic tumor- infiltrating immune cells influence the prognostic landscape also in cervical cancer, which is highly related to and modulated by HPV [15].

Several studies demonstrated the overexpression of programmed death ligand 1(PD-L1) in cervical SCC and its potential utility [16-19]. Moreover, different clinical trials have been conducted regarding immune checkpoint inhibitors (ICIs) and tumor-infiltrating lymphocytes (TILs), including programmed death 1(PD-1), PD-L1, programmed death ligand 2(PD-L2), and cytotoxic T-lymphocyte-associated protein 4(CTLA-4) [20-22].



As mentioned above, all these studies are regarding mostly SCC; on the other hand, few and contrasting data are available specifically on ADC, due to the small number of patients included in these cohorts. Similarly, the mismatch repair proteins (MMR) are still under investigation, although defects in this repair system can increase mutation rates and promote cancer initiation and progression, such as in patients with Lynch Syndrome [23,24].

Very recently has been published an investigation evaluating the expression of PD-L1 and the MMR status, trying to highlight the potential correlation with clinicopathological features [25], in a mono-series of 39 patients. Although it was a small sample size, it seems to be a correct approach for studying this particular subgroup of cervical cancer. Previous studies, such as Bonneville, et al. [26] did not analyze separately SCC from ADC [26], consequently a potential different biological status couldn't emerge. Evaluating a cohort formed only by ADCs, highlighted a significantly higher number of MMRd cases, suggesting a pivotal role of this dysregulation in adenocarcinoma's oncogenesis. Moreover, due to the correlation between tumor-infiltrating lymphocytes (CD8+), PD-L1 expression and MMRd tumors observed by others author among gynecologic malignancies, it focused the attention also on PD-L1 protein expression.

Comparing to the contradictory results of previous studies [27-32], the novel research [25] showed no PD-L1 expression (<1%) in ADCs, independently of the MMR status or other clinic-pathological variables, with the only exception of invasive stratified mucin cancer (iSMC), which has been recently described as a peculiar morphologic histotype with evident HPV infection-related features, and frequently associated with a brisk tumor inflammatory infiltrate [33].

Thus, the emerging data underlined the potential role of MMRd as an early event in ADC tumorigenesis, considering that either invasive or in situ lesions can host this molecular alteration, supporting this assumption. Of course, distinguishing the germline or somatic nature of MMRd mutations remains crucial, particularly because of the increased lifetime risk of several solid malignancies in patients harbouring a germline mutation. This underpins the importance of the screening for Lynch syndrome also in ADC, confirming the importance of genetic counselling. On the other hand, PD-L1 seems to not play a pivotal role in ADC, except for iSMC. Of course, this interesting exception need to be further investigated, anyway it reveals the heterogeneity of ADCs one more time.

## Conclusion

In conclusion, a broad spectrum of protein biomarkers is still being investigated, considering not only the neoplastic cell population, but also the complex interactions with TME and cervical microbiota [34] to predict prognosis and treatment response. May be, finding a predictive unique marker is utopian, while evaluating multiple expression levels of proteins in a combined analyse could be the right way to run across.

## Conflicts of Interest

The authors declare no conflict of interest.

## References

- (2020) WHO and IARC: Who classification of tumours: Female genital tumours. IARC: Lyon.
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, et al. (2018) Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 68(6): 394-424.
- HO Smith, MF Tiffany, CR Qualls, CR Key (2000) The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the united states-a 24-year population-based study. *Gynecol Oncol* 78(2): 97-105.
- (2014) World Health O: Comprehensive cervical cancer control: A guide to essential practice. 2nd edn. World Health Organization: Geneva pp. 364.
- Ojesina AI, Lichtenstein L, Freeman SS, Pedamallu CS, Imaz Rosshandler I, et al. (2014) Landscape of Genomic Alterations in Cervical Carcinomas. *Nature* 506: 371-375.
- Scholl S, Popovic M, Girard E, Dureau S, Mandic A, et al. (2019) Clinical and Genetic Landscape of Treatment Naive Cervical Cancer: Alterations in PIK3CA and in Epigenetic Modulators Associated with Sub-Optimal Outcome. *EBioMedicine* 43: 253-260.
- Vivanco I, Sawyers CL (2002) The Phosphatidylinositol 3-Kinase AKT Pathway in Human Cancer. *Nat Rev Cancer* 2(7): 489-501.
- Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, et al. (2004) High Frequency of Mutations of the PIK3CA Gene in Human Cancers. *Science* 304(5670): 554.
- Schuurbiers OCJ, Kaanders JHAM, van der Heijden HFM, Dekhuijzen RPN, Oyen WJG, et al. (2009) The PI3-K/AKT-Pathway and Radiation Resistance Mechanisms in Non-Small Cell Lung Cancer. *J Thorac Oncol* 4(6): 761-767.
- Millis SZ, Ikeda S, Reddy S, Gatalica Z, Kurzrock R (2016) Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors. *JAMA Oncol* 2(12): 1565-1573.
- Millis SZ, Jardim DL, Albacker L, Ross JS, Miller VA, et al. (2019) Phosphatidylinositol 3-Kinase Pathway Genomic Alterations in 60,991 Diverse Solid Tumors Informs Targeted Therapy Opportunities. *Cancer* 125(7): 1185-1199.
- Lee S, Shin HJ, Han IO, Hong EK, Park SY, et al. (2007) Tumor Carbonic Anhydrase 9 Expression Is Associated with the Presence of Lymph Node Metastases in Uterine Cervical Cancer. *Cancer Sci* 98(3): 329-333.
- Huang M, Chen Q, Xiao J, Yao T, Bian L, et al. (2014) Overexpression of Hypoxia-Inducible Factor-1 $\alpha$  Is a Predictor of Poor Prognosis in Cervical Cancer: A Clinicopathologic Study and a Meta-Analysis. *Int J Gynecol Cancer* 24(6): 1054-1064.
- Fu Z, Chen D, Cheng H, Wang F (2015) Hypoxia-Inducible Factor-1 $\alpha$  Protects Cervical Carcinoma Cells from Apoptosis Induced by Radiation via Modulation of Vascular Endothelial Growth Factor and P53 under Hypoxia. *Med Sci Monit* 21: 318-325.
- Shamseddine AA, Burman B, Lee NY, Zamarin D, Riaz N (2021) Tumor Immunity and Immunotherapy for HPV-Related Cancers. *Cancer Discov* 11(8): 1896-1912.
- Schellens JHM, Marabelle A, Zeigenfuss S, Ding J, Pruitt SK, et al. (2017) Pembrolizumab for previously treated advanced cervical squamous cell cancer: Preliminary results from the phase 2 keynote-158 study. *J Clin Oncology* 35(15suppl): 5514-5514.

17. Karpathiou G, Chauleur C, Mobarki M and Peoch M (2020) The immune checkpoints cta-4 and pd-11 in carcinomas of the uterine cervix. *Pathol Res Pract* 216(1): 152782.
18. Heeren AM, Punt S, Bleeker MC, Gaarenstroom KN, van der Velden J, et al. (2016) Prognostic effect of different pd-11 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix. *Mod Pathol* 29(7): 753-763.
19. Ishikawa M, Nakayama K, Nakamura K, Yamashita H, Ishibashi T, et al. (2020) High pd-1 expression level is associated with an unfavorable prognosis in patients with cervical adenocarcinoma. *Arch Gynecol Obstet* 302(1): 209-218.
20. Di Tucci C, Schiavi MC, Faiano P, D Oria O, Prata G, et al. (2018) Therapeutic vaccines and immune checkpoints inhibition options for gynecological cancers. *Crit Rev Oncol Hematol* 128: 30-42.
21. Burmeister CA, Khan SF, Schäfer G, Mbatani N, Adams T, et al. (2022) Cervical cancer therapies: Current challenges and future perspectives. *Tumour Virus Res.* 13: 200238.
22. Jazaeri AA, Zsiros E, Amaria RN, Artz AS, Edwards RP, et al. (2019) Monk Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma. *J Clin Oncol* 37: 2538.
23. Li GM (2013) DNA mismatch repair and the DNA damage response. Elsevier.
24. Graham VWJ, Putnam CD, Kolodner RD (2018) DNA mismatch repair: Mechanisms and cancer genetics. Elsevier.
25. Pistolesi S, Fanelli GN, Giudice F, Garbini F, Naccarato AG, et al. (2023) Cervical Adenocarcinoma: A Still Under-investigated Malignancy. *Anticancer Res* 43(1): 53-58.
26. Bonneville R, Krook MA, Kautto EA, Miya J, Wing MR, et al. (2017) Landscape of microsatellite instability across 39 cancer types. *JCO precision oncology*. (PO.17.00073).
27. Liu Y, Wu L, Tong R, Yang F, Yin L, et al. (2019) Pd-1/pd-11 inhibitors in cervical cancer. *Front pharmacol* 10: 65.
28. Rotman J, den Otter LAS, Bleeker MCG, Samuels SS, Heeren AM, et al. (2020) Pd-11 and pd-12 expression in cervical cancer: Regulation and biomarker potential. *Front immunol* 11: 596825.
29. Yang W, Lu YP, Yang YZ, Kang JR, Jin YD, et al. (2017) Expressions of programmed death (pd)-1 and pd-1 ligand (pd-11) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status. *J Obstet Gynaecol Res* 43(10): 1602-1612.
30. Meng Y, Liang H, Hu J, Liu S, Hao X, et al. (2018) Pd-11 expression correlates with tumor infiltrating lymphocytes and response to neoadjuvant chemotherapy in cervical cancer. *J Cancer* 9(16): 2938-2945.
31. Enwere EK, Kornaga EN, Dean M, Koulis TA, Phan T, et al. (2017) Expression of pd-11 and presence of cd8-positive t cells in pre-treatment specimens of locally advanced cervical cancer. *Mod Pathol* 30(4): 577-586.
32. Karim R, Jordanova ES, Piersma SJ, Kenter GG, Chen L, et al. (2009) Tumor-expressed b7-h1 and b7-dc in relation to pd-1+ t-cell infiltration and survival of patients with cervical carcinoma. *Clin Cancer Res* 15(20): 6341-6347.
33. Lastra RR, Park KJ, Schoolmeester JK (2016) Invasive stratified mucin-producing carcinoma and stratified mucin-producing intraepithelial lesion (smile). *Am J Surg Pathol* 40(2): 262-269.
34. Helmink BA, Khan MAW, Hermann A, Gopalakrishnan V, Wargo JA (2019) The Microbiome, Cancer, and Cancer Therapy. *Nat Med* 25(3): 377-388.